Synta Pharmaceuticals (SNTA) Said SYMMETRYSM Trial Did Not Achieve Statistical Significance
More News related to SNTA
- Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090
- Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
- Synta Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
- Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results
More News related to FDA
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced the preliminary results of the Phase 3 SYMMETRYSM trial of elesclomol in combination with paclitaxel in metastatic melanoma.
These results show a trend towards improvement in PFS, which did not achieve statistical significance (p=0.111; stratified log-rank test).
A statistically significant PFS improvement was achieved, however, in the normal LDH population, which constituted just over 2/3 of total evaluable patients in this trial.
More from Release
Related Categories
FDAStocks Mentioned
+0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
